Literature DB >> 8599402

Problem of diagnosis in postmortem brain studies of schizophrenia.

C Hill1, N Keks, S Roberts, K Opeskin, B Dean, A MacKinnon, D Copolov.   

Abstract

OBJECTIVE: The purpose of this study was to determine 1) the reliability of diagnoses of schizophrenia at coronal autopsy and 2) the degree to which the use of different diagnostic instruments for schizophrenia would affect postmortem brain research.
METHOD: Eighty-three subjects, recorded at coronal autopsy as having had schizophrenia, were referred for neurochemistry studies. The diagnoses reported to the state coroner's office were reevaluated by a review of psychiatric case histories by clinicians using semistructured assessment and diagnostic criteria.
RESULTS: The application of DSM-III-R, Research Diagnostic Criteria (RDC), ICD-10, Schneiderian, and Feighner criteria to the diagnosis of the 83 subjects revealed that 63.9%, 48.2%, 48,2%, 43.4%, and 42.2%, respectively, met the criteria for schizophrenia. Highest concordance was between the RDC and ICD-10 systems, while lowest concordance was between the RDC and Schneider systems.
CONCLUSIONS: These data suggest that unless carefully reviewed, diagnosis may be a major confounding factor in postmortem studies of brain tissue from subjects with schizophrenia.

Entities:  

Mesh:

Year:  1996        PMID: 8599402     DOI: 10.1176/ajp.153.4.533

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  32 in total

1.  Psychopharmacogenetics and psychiatric genetics: similar methodological challenges.

Authors:  M Maziade; M A Roy; C Mérette; L Bissonnette; R Quirion; R Palmour
Journal:  J Psychiatry Neurosci       Date:  1999-05       Impact factor: 6.186

2.  The carbohydrate deposits detected by histochemical methods in the molecular layer of the dentate gyrus in the hippocampal formation of patients with schizophrenia, Down's syndrome and dementia, and aged person.

Authors:  A Nishimura; K Ikemoto; K Satoh; Y Yamamoto; S Rand; B Brinkmann; K Nishi
Journal:  Glycoconj J       Date:  2000-11       Impact factor: 2.916

Review 3.  First rank symptoms for schizophrenia.

Authors:  Karla Soares-Weiser; Nicola Maayan; Hanna Bergman; Clare Davenport; Amanda J Kirkham; Sarah Grabowski; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-01-25

4.  Postmortem diagnosis and toxicological validation of illicit substance use.

Authors:  Elin Lehrmann; Zoan R Afanador; Amy Deep-Soboslay; Gloria Gallegos; William D Darwin; Ross H Lowe; Allan J Barnes; Marilyn A Huestis; Jean L Cadet; Mary M Herman; Thomas M Hyde; Joel E Kleinman; William J Freed
Journal:  Addict Biol       Date:  2008-01-14       Impact factor: 4.280

5.  Catechol-O-methyltransferase (COMT) genotypes are associated with varying soluble, but not membrane-bound COMT protein in the human prefrontal cortex.

Authors:  Georgia M Parkin; Madhara Udawela; Andrew Gibbons; Elizabeth Scarr; Brian Dean
Journal:  J Hum Genet       Date:  2018-09-14       Impact factor: 3.172

6.  Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia.

Authors:  Ali Torkamani; Brian Dean; Nicholas J Schork; Elizabeth A Thomas
Journal:  Genome Res       Date:  2010-03-02       Impact factor: 9.043

7.  AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder.

Authors:  Andrew Stuart Gibbons; Lucy Brooks; Elizabeth Scarr; Brian Dean
Journal:  J Affect Disord       Date:  2011-10-28       Impact factor: 4.839

8.  Transcriptional correlates of human substance use.

Authors:  Elin Lehrmann; William J Freed
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

9.  No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus.

Authors:  L Naylor; B Dean; A Pereira; A Mackinnon; A Kouzmenko; D Copolov
Journal:  Mol Med       Date:  1998-10       Impact factor: 6.354

10.  Evidence for disruption of sphingolipid metabolism in schizophrenia.

Authors:  Sujatha Narayan; Steven R Head; Timothy J Gilmartin; Brian Dean; Elizabeth A Thomas
Journal:  J Neurosci Res       Date:  2009-01       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.